Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3Phase 3 2Phase NA 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 47NIH 5NETWORK 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

ONC206 1Mn-PyC3A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Meningioma × Clear all
NCT07428616 2026-05-27

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Exelixis

Phase 2 Recruiting
100 enrolled
CNS

Brain Neoplasms, Meningioma

NCT07533942 2026-04-16

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Jazz Pharmaceuticals

Phase 2 Not yet recruiting
30 enrolled
CNS

Meningioma

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

Phase 2 Completed
18 enrolled
CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡